In contrast with the present study, Nakamura et al. [19] showed that NT-proBNP levels were not significantly changed in patients with HF and CKD after 3 months from the introduction of HIF-PH inhibitors, despite an increase in Hb levels. This evidence concerns the gene GSTM1 and chronic kidney disease.